Third, the high-affinity EGFR model predicts that even minimal or residual activity of EGFR in human tumors treated with EGFR kinase inhibitors may be sufficient for tumor growth and may therefore underlie tumor resistance to such treatments. The gene discussed is EGFR; the disease is neoplasm.